Essential Thrombocythemia: A Review

Area of Science:

• Hematology
• Oncology

Background:

• Essential thrombocythemia (ET) is a clonal myeloproliferative neoplasm characterized by excessive platelet production.
• ET is associated with an elevated risk of thrombosis and bleeding complications.
• The annual incidence of ET in the US is approximately 1.5 per 100,000 individuals.

Purpose of the Study:

• To summarize the clinical characteristics, risk factors, and management strategies for essential thrombocythemia.
• To highlight the increased risks of thrombosis and hemorrhage in ET patients.
• To discuss therapeutic approaches based on individual patient risk profiles.

Main Methods:

• Review of existing literature on essential thrombocythemia.
• Analysis of patient data regarding incidence, genetic mutations, and clinical outcomes.
• Evaluation of treatment efficacy for thrombosis prevention.

Main Results:

• ET patients present with platelet counts ≥450 × 10^9/L and are at increased risk of arterial (11%) and venous thrombosis (7%), and hemorrhage (8%).
• Key genetic drivers include JAK2 (64%), CALR (23%), and MPL (4%), influencing thrombosis risk.
• Risk factors for thrombosis include prior thrombosis, age >60, JAK2 mutation, and cardiovascular factors.
• Low-dose aspirin is recommended for most ET patients; hydroxyurea significantly reduces thrombotic events in high-risk individuals.

Conclusions:

• Essential thrombocythemia necessitates risk-stratified management to mitigate thrombosis, hemorrhage, and potential progression to myelofibrosis or acute myeloid leukemia.
• Treatment strategies involve low-dose aspirin for risk reduction and cytoreductive therapy (e.g., hydroxyurea) for high-risk patients.
• Ongoing monitoring is crucial for managing ET and its associated complications.